ANKRD22

Across TCGA pan-cancer cohorts, ANKRD22 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ANKRD22’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ANKRD22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ANKRD22 is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

THCA, LUAD, and KIRP are the cancer types where ANKRD22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	III,IV	+1.311	<.001	10	view →
LUAD	Male	II,III,IV	+2.713	<.001	9	view →
KIRP	Female	All	−1.273	<.001	9	view →
COAD	All	II,III,IV	+0.954	<.001	7	view →
LUSC	Male	All	+2.171	<.001	6	view →
UCEC	All	All	+2.101	<.001	6	view →
BRCA	All	III,IV	+1.801	<.001	6	view →
PAAD	All	All	+1.442	.005	4	view →
CHOL	Female	All	+3.390	<.001	3	view →
KICH	All	III,IV	−1.660	.004	3	view →
HNSC	Female	All	−1.035	.008	3	view →
STAD	All	All	+1.122	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ANKRD22–THCA

Open the THCA breakdown →